Signal
FDA alleges data manipulation in Amgen drug; Erasca's promising RAS drug faces market skepticism
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-04-28 13:57 UTCUpdated 2026-04-28 14:08 UTC
rss
clinical_trialsfdadrug_developmentsafety_signals
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
The FDA accused the original developer of Amgen's Tavneos of hiding and altering study data, raising regulatory concerns. Meanwhile, Erasca published phase 1 data for its pan-RAS drug showing a 'home run' profile, but the stock dropped 42% amid investor skepticism.
Entities
AmgenErascaRocket PharmaTavneos
Score total
0.97
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
Why now
- FDA's data manipulation allegations impact confidence in Tavneos' approval.
- Erasca's phase 1 data release coincides with a sharp stock drop, highlighting market volatility.
- Recent voucher sale by Rocket Pharma reflects ongoing shifts in biotech regulatory incentives.
Why it matters
- Data integrity is critical for regulatory approvals and patient safety.
- Promising clinical data can face market skepticism impacting biotech valuations.
- Priority review vouchers remain valuable assets in biotech funding and regulatory strategy.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: medium
Recurring claims
- Erasca's pan-RAS drug shows a best-in-class profile with strong phase 1 data
- FDA alleges that Tavneos' original developer hid and altered clinical study data
How sources frame it
- FDA: questioning
- Erasca: supportive
All evidence
All evidence
Erasca has backed up bullish claims about its pan-RAS drug having a best-in-class profile, publishing phase 1 data that an analyst said reveal a “home run profile.”
Fierce Biotech · fiercebiotech.com · 2026-04-28 14:08 UTC
FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results
BioPharma Dive · biopharmadive.com · 2026-04-28 13:57 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Biotech (1)
- BioPharma Dive (1)
Top origin domains (this list)
- fiercebiotech.com (1)
- biopharmadive.com (1)